Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) EBIT (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of EBIT data on record, last reported at -$87.2 million in Q4 2025.

  • For Q4 2025, EBIT fell 55.56% year-over-year to -$87.2 million; the TTM value through Dec 2025 reached -$287.4 million, down 47.31%, while the annual FY2025 figure was -$287.4 million, 47.31% down from the prior year.
  • EBIT reached -$87.2 million in Q4 2025 per CLDX's latest filing, down from -$73.6 million in the prior quarter.
  • Across five years, EBIT topped out at $36.0 million in Q4 2021 and bottomed at -$87.2 million in Q4 2025.
  • Average EBIT over 5 years is -$38.4 million, with a median of -$38.5 million recorded in 2022.
  • Peak YoY movement for EBIT: surged 245.47% in 2021, then crashed 177.36% in 2022.
  • A 5-year view of EBIT shows it stood at $36.0 million in 2021, then plummeted by 177.36% to -$27.9 million in 2022, then crashed by 70.8% to -$47.6 million in 2023, then decreased by 17.64% to -$56.0 million in 2024, then crashed by 55.56% to -$87.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$87.2 million in Q4 2025, -$73.6 million in Q3 2025, and -$63.9 million in Q2 2025.